HSPA1A and cardiac rhythm disease: A concern to be addressed will be pleiotropic effects of such therapies – for example, inhibition of HSP70 to relieve CHIP-mediated degradation of ΔF508 CFTR could also impair HSP70-dependent folding of hERG, leading to cardiac arrhythmias in CF patients.